PF-03187207

· Bausch & Lomb Incorporated

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for PF-03187207, covering 2020-08-27 to 2020-08-27. Get the full timeline:

Most recent: Clinical Trial Update: A Phase 2, Dose Finding Study of PF-03187207 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension. [Phase 2]

See pricing